Thus, TLR2/4-mediated IL-17A signaling is required in retinal vascular degeneration, indicating that targeting TLR2/4-mediated IL-17A signaling is a novel strategy to promote revascularization and treat degenerative diseases. This evidence concerns the gene IL17A and neurodegenerative disease.